Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902

被引：0

作者：

Kenya Kanazawa

Hiroshi Yokouchi

Xintao Wang

Takashi Ishida

Yuka Fujita

Satoru Fujiuchi

Toshiyuki Harada

Masao Harada

Kei Takamura

Satoshi Oizumi

Ichiro Kinoshita

Yutaka Katsuura

Osamu Honjo

Tetsuya Kojima

Hirotoshi Dosaka-Akita

Hiroshi Isobe

Mitsuru Munakata

Masaharu Nishimura

机构：

[1] Fukushima Medical University School of Medicine,Department of Pulmonary Medicine

[2] Fukushima Medical University Hospital,Clinical Oncology Center

[3] National Hospital Organization Asahikawa Medical Center,Department of Respiratory Medicine

[4] Japan Community Health Care Organization Hokkaido Hospital,Center for Respiratory Disease

[5] National Hospital Organization Hokkaido Cancer Center,Department of Respiratory Medicine

[6] Hokkaido P. W. F. A. C. Obihiro-Kosei General Hospital,First Department of Medicine

[7] Hokkaido University School of Medicine,First Department of Medicine

[8] Hokkaido University Graduate School of Medicine,Department of Medical Oncology

[9] Saiseikai Fukushima General Hospital,Department of Pulmonary Medicine

[10] Hokkaido P. W. F. A. C. Sapporo-Kosei General Hospital,Department of Respiratory Medicine

[11] KKR Sapporo Medical Center,Department of Medical Oncology and Respiratory Medicine

来源：

Cancer Chemotherapy and Pharmacology | 2014年 / 74卷

关键词：

Non-squamous non-small cell lung cancer; Carboplatin; Pemetrexed; Genetic polymorphisms; Methylenetetrahydrofolate reductase (MTHFR); Thymidylate synthase (TS);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1149 / 1157

页数：8

共 50 条

[31] Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.
Nagel, S.
Groeschel, A.
Sebastian, M.
Andreas, S.
Mueller, T.
Schneller, F.
Guetz, S.
Leschinger, M. I.
Buettner, H.
Reck, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[32] A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Spigel, D. R.
Greco, F. A.
Shipley, D.
Ervin, T. J.
Lubiner, E. T.
Peyton, J. D.
Bames, E. K.
Thompson, D. S.
Burris, H. A., III
Hainsworth, J. D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[33] PHASE II STUDY OF PEMETREXED plus CARBOPLATIN AS FIRST LINE THERAPY FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITHOUT EGFR MUTATION. : CENTRAL JAPAN LUNG STUDY GROUP (CJLSG) 0906 TRIAL
Kimura, Tomoki
Taniguchi, Hiroyuki
Saka, Hideo
Yukita, Yousuke
Kojima, Eiji
Ogasawara, Tomohiko
Yamamoto, Masashi
Kondo, Masashi
Suzuki, Ryujiro
Imaizumi, Kazuyoshi
Ikeda, Takuya
Nomura, Fumio
Tanikawa, Yoshimasa
Saito, Hiroshi
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1166 - S1167
[34] TOLERANCE AND EFFICACY OF PEMETREXED-CISPLATIN FOR ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER A GALICIAN LUNG CANCER GROUP STUDY
Senin, Clara
Campos, Begona
Jose Villanueva, Maria
Firvida, J. L.
Baron, Francisco
Amenedo, Margarita
Afonso, Javier
Lazaro, Martin
Varela, S.
Grande, C.
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1277 - S1277
[35] Efficacy and Safety of Pemetrexed-Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer - a Galician Lung Cancer Group Study
Senin, C.
Varela, S.
Huidobro, G.
Firvida, J. L.
Baron, F.
Amenedo, M.
Afonso, F. J.
Lazaro, M.
Campos, B.
Casal, J.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S624 - S624
[36] Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer
Zhang, Liang
Ou, Wei
Liu, Qianwen
Li, Ning
Liu, Li
Wang, Siyu
THORACIC CANCER, 2014, 5 (01) : 50 - 56
[37] Phase II trial of carboplatin and pemetrexed combination in elderly patients with advanced non-squamous non small cell lung cancer (NS-NSCLC). A Galician Lung Cancer Group Study.
Areses Manrique, Ma Carmen
Fernandez Nunez, Natalia
Covela Rua, Marta
Alonso Herrero, Ana
Villanueva Silva, Maria Jose
Afonso Afonso, Francisco J.
Esquerdo, Gaspar
Campos Balea, Begona
Lazaro Quintela, Martin
Garcia Mata, Jesus
Vazquez-Estevez, Sergio
Anido Herranz, Urbano
Casal Rubio, Joaquin
Firvida Perez, Jose Luis
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[38] RANDOMIZED PHASE II STUDY OF PEMETREXED PLUS CARBOPLATIN FOLLOWED BY PEMETREXED VERSUS PACLITAXEL PLUS CARBOPLATIN FOLLOWED BY PEMETREXED IN ADVANCED NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (LOGIK 0904)
Shiraishi, Yoshimasa
Inoue, Koji
Takeshita, Masafumi
Harada, Taishi
Tashiro, Naoki
Seto, Takashi
Imanaga, Tomotoshi
Fujimoto, Noriko
Nakagaki, Noriaki
Kawasaki, Masayuki
Kishimoto, Junji
Takayama, Koichi
Ichinose, Yukito
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S403 - S404
[39] Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Young Hak Kim
Masataka Hirabayashi
Shinji Kosaka
Junichi Nikaidoh
Yasumichi Yamamoto
Masatoshi Shimada
Toshiya Toyazaki
Hiroki Nagai
Yuichi Sakamori
Michiaki Mishima
Cancer Chemotherapy and Pharmacology, 2013, 71 : 1445 - 1451
[40] Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial
Gervais, Radj
Robinet, Gilles
Clement-Duchene, Christelle
Denis, Fabrice
El Kouri, Claude
Martin, Philippe
Chouaki, Nadia
Bourayou, Nawel
Morere, Jean-Francois
LUNG CANCER, 2013, 80 (02) : 185 - 190

← 1 2 3 4 5 →